Sex: F
Vaccine: COVID19
Symptoms: Body temperature, COVID-19, Interchange of vaccine products
Clinical narrative: The HCP reported about one week ago, his son's wife became infected with a mild case of Omicron; Pfizer COVID-19 vaccine for her first and second doses; This spontaneous case was reported by a physician and describes the occurrence of COVID-19 (The HCP reported about one week ago, his son's wife became infected with a mild case of Omicron) and INTERCHANGE OF VACCINE PRODUCTS (Pfizer COVID-19 vaccine for her first and second doses) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Pfizer and Pfizer. Past adverse reactions to the above products included No adverse event with Pfizer and Pfizer.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced COVID-19 (The HCP reported about one week ago, his son's wife became infected with a mild case of Omicron) and INTERCHANGE OF VACCINE PRODUCTS (Pfizer COVID-19 vaccine for her first and second doses). At the time of the report, COVID-19 (The HCP reported about one week ago, his son's wife became infected with a mild case of Omicron) outcome was unknown and INTERCHANGE OF VACCINE PRODUCTS (Pfizer COVID-19 vaccine for her first and second doses) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 100 (High) 100 Fahrenheit.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication were provided. No treatment details were provided.  Company comment: This case concerns a female patient of unknown age, with no medical history reported, who experienced the adverse event of special interest of COVID-19 an unknown time after the booster dose of mRNA-1273. Previously, the patient received dose 1 and 2 of Pfizer COVID-19 vaccine, so lack of efficacy cannot be concluded for this case. The patient's clinical presentation was an upper respiratory tract infection. Based on the current available information, the mRNA-1273 vaccine does not contain a virus capable of causing COVID-19 infection after vaccination, therefore, the causality for COVID-19 is not applicable. The benefit-risk relationship of mRNA-1273 is not affected by this report.   Reporter did not allow further contact; Sender's Comments: This case concerns a female patient of unknown age, with no medical history reported, who experienced the adverse event of special interest of COVID-19 an unknown time after the booster dose of mRNA-1273. Previously, the patient received dose 1 and 2 of Pfizer COVID-19 vaccine, so lack of efficacy cannot be concluded for this case. The patient's clinical presentation was an upper respiratory tract infection. Based on the current available information, the mRNA-1273 vaccine does not contain a virus capable of causing COVID-19 infection after vaccination, therefore, the causality for COVID-19 is not applicable. The benefit-risk relationship of mRNA-1273 is not affected by this report.